PROCEPT BioRobotics Corp's Chief Strategy/Marketing Officer Pooja Sharma filed a Form 4 on November 6, 2026, disclosing the disposition of 4,710 shares of common stock through the company's sell-to-cover process for tax withholding obligations connected to restricted stock unit vesting.
Coastlands Capital LP filed an initial statement of beneficial ownership (Form 3) with the SEC on November 6, 2026, disclosing holdings in Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) as of the event date of November 6, 2026.
Net Power Inc. President and COO Marc Horstman filed a Form 4 on November 6, 2026, disclosing a board-approved amendment to a previously granted stock option that extended the post-termination exercise period without altering other terms.
Sardar Biglari, a director and 10% owner of El Pollo Loco Holdings, Inc. (NASDAQ:LOCO), filed a statement of changes in beneficial ownership on November 6, 2026, reporting the sale of 19,153 shares of common stock across two transactions on November 4 and November 5, …
GlobalFoundries Inc. Chief Legal Officer L. Azar Samak filed a Form 4 on November 6, 2026, disclosing the sale of 335 ordinary shares on November 5, 2026, pursuant to a Rule 10b5-1 trading plan.
Director Ganesh Moorthy filed a Form 4 with the SEC on November 6, 2026, disclosing an open market purchase of GlobalFoundries Inc. ordinary shares on November 5, 2026.
Director Patricia F. Elcan filed a statement of changes in beneficial ownership with the SEC on November 6, 2026, reporting transactions in HCA Healthcare, Inc. common stock dated November 4, 2026.
Central Garden & Pet Co Chief Accounting Officer Howard Machek filed a Form 4 on November 6, 2026, reporting the exercise of stock options and a related share withholding transaction dated November 5, 2026.
Thomas F. Frist III, a director and 10% owner of HCA Healthcare, Inc. (NYSE:HCA), filed a Form 4 on November 6, 2026, disclosing a transfer of 555,500 Hercules Holding II units to trusts for the benefit of his children on November 4, 2026.
Director Rachel Humphrey of Pyxis Oncology, Inc. filed a Form 4 on November 6, 2026, disclosing the acquisition of a stock option covering 34,500 shares of common stock at an exercise price of $1.66 per share.